| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/25/2005 | US6846674 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and |
| 01/25/2005 | US6846672 Mitogenic oxygenase regulators |
| 01/25/2005 | US6846670 Expressing heterologous nucleotide sequences in cells; obtain vascular cells, incubate with herpes virus, monitor propagation of virus in central nervous system |
| 01/25/2005 | US6846667 Virulence genes and proteins, and their use |
| 01/25/2005 | US6846665 Method of producing a recombinant adeno-associated virus, suitable means for producing the same and use thereof for producing a medicament |
| 01/25/2005 | US6846652 As vaccines and anticancer agents |
| 01/25/2005 | US6846650 Nucleotide sequences coding polypeptide for use in the imaging, diagnosis, treatment classification and prevention of lung cancer |
| 01/25/2005 | US6846623 LGMD gene coding for a calcium dependent protease |
| 01/25/2005 | US6846477 One dose vaccination with Mycoplasma hyopneumoniae |
| 01/25/2005 | CA2388674C Inhibitors of endo-exonuclease activity for treating cancer |
| 01/25/2005 | CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes |
| 01/20/2005 | WO2005005984A1 Method of diagnosing disease relating to endometriosis |
| 01/20/2005 | WO2005005637A2 Herpes simplex virus comprising a genetically modified glycoprotein d |
| 01/20/2005 | WO2005005630A2 Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| 01/20/2005 | WO2005005626A1 Yellow fever mosquito deoxyribonucleoside kinases and its use |
| 01/20/2005 | WO2005005613A2 Dsrna induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein |
| 01/20/2005 | WO2005005603A2 Method for inducing an immune response to cancer antigen |
| 01/20/2005 | WO2005005599A2 Modulation of c-reactive protein expression |
| 01/20/2005 | WO2005005466A2 Nucleic and protein sequences from the hxhv virus and uses thereof |
| 01/20/2005 | WO2005004879A1 Intravascular delivery of non-viral nucleic acid |
| 01/20/2005 | WO2005004814A2 Sirt1 and genetic disorders |
| 01/20/2005 | WO2005004794A2 Method of treating neurodegenerative disease |
| 01/20/2005 | WO2004106411A3 Biodegradable poly(beta-amino esters) and uses thereof |
| 01/20/2005 | WO2004096126A3 Treating hepatocellular carcinomas using therapeutic viruses |
| 01/20/2005 | WO2004085673A3 Compositions and methods of using hexokinase v |
| 01/20/2005 | WO2004076648A9 Clinically relevant animal model of human breast cancer and vegf involement in desmoplastic response. |
| 01/20/2005 | WO2004043977A3 2’-fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| 01/20/2005 | WO2004034995A3 Methods and reagents for inducing immunity |
| 01/20/2005 | WO2003103017A3 Method and system of determining chamber seasoning condition by optical emission |
| 01/20/2005 | WO2003082302A9 Bioadhesive directed somatic cell therapy |
| 01/20/2005 | WO2003072114A8 Vascular therapeutics |
| 01/20/2005 | WO2003066881A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 01/20/2005 | US20050014714 Gene delivery to organs |
| 01/20/2005 | US20050014713 Controlling gene expression;diagnosis, therapy of disease; antidiabetic agents; insulin resistance |
| 01/20/2005 | US20050014710 Compositions and methods relating to prostate specific genes and proteins |
| 01/20/2005 | US20050014695 Uses of a chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes |
| 01/20/2005 | US20050014692 Isolate nucleic acids; intensify stimulated insulin elimination; antidiabetic agents |
| 01/20/2005 | US20050014689 Remedies for life style-related diseases or cibophobia and method of screening the same |
| 01/20/2005 | US20050014688 Inducer of apoptosis |
| 01/20/2005 | US20050014263 Materials and methods for delivery and expression of heterologous DNA in vertebrate cells |
| 01/20/2005 | US20050014262 Viral expression vector for use as heterologous gene and/or therapeutic protein delivery tools; genetic vaccine |
| 01/20/2005 | US20050014259 Nucleic acid delivery |
| 01/20/2005 | US20050014258 Methods for altering cell fate |
| 01/20/2005 | US20050014257 Modulation of C-reactive protein expression |
| 01/20/2005 | US20050014222 Phosphatases which activate map kinase pathways |
| 01/20/2005 | US20050014187 Novel polypeptide hormone phosphatonin |
| 01/20/2005 | US20050014180 Growth differentiation factor-16 |
| 01/20/2005 | US20050014166 Compositions and systems for the regulation of genes |
| 01/20/2005 | US20050014158 Using presence of polymorphic sequences in gene associated with phospholipase to diagnose, prognose and treat non-insulin dependent diabetes mellitus and obesity |
| 01/20/2005 | US20050013829 Novel growth factor Opa1 and uses thereof |
| 01/20/2005 | US20050013827 Novel molecules of the herpesvirus-entry-mediator-related protein family and uses thereof |
| 01/20/2005 | US20050013825 Vaccine containing the catalytic subunit of telomerase for treating cancer |
| 01/20/2005 | US20050013823 Administering to animal at 3 to 10 days of age; swine |
| 01/20/2005 | US20050013808 Nitroreductase enzymes |
| 01/20/2005 | US20050013806 Culturing genetically altered stem cells on concave lens surface and placing onto cornea |
| 01/20/2005 | CA2532535A1 Method of diagnosing disease relating to endometriosis |
| 01/20/2005 | CA2532150A1 Method of evaluating compound efficacious in treating obesity |
| 01/20/2005 | CA2531629A1 Medicinal composition containing nf-.kappa.b decoy for treating and preventing respiratory diseases and method of using the same |
| 01/20/2005 | CA2531242A1 Method of altering cell properties by administering rna |
| 01/20/2005 | CA2530967A1 Inhibition of stress-induced ligand-dependent egfr activation |
| 01/20/2005 | CA2527537A1 Modulation of c-reactive protein expression |
| 01/19/2005 | EP1498129A1 Use of adenoviruses mutated in the va genes for cancer treatment |
| 01/19/2005 | EP1497659A2 An ephrin-b receptor protein involved in carcinoma |
| 01/19/2005 | EP1497658A2 Protein involved in cancer |
| 01/19/2005 | EP1497656A2 Diagnosis of carcinoma using raig1 polypeptides |
| 01/19/2005 | EP1497642A2 Gene amplification in cancer |
| 01/19/2005 | EP1497470A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 01/19/2005 | EP1497467A2 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 01/19/2005 | EP1497462A2 Genomic screen for epigenetically silenced genes associated with cancer |
| 01/19/2005 | EP1497442A2 Biologic modulations with nanoparticles |
| 01/19/2005 | EP1497440A2 Stable adenoviral vectors and methods for propagation thereof |
| 01/19/2005 | EP1497439A2 Recombining viral vectors for the tetracycline-regulated expression of genes |
| 01/19/2005 | EP1497438A1 Means and methods for the production of adenovirus vectors |
| 01/19/2005 | EP1497436A1 Compositions for delivering enzymes involved in amino acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolic disorders using such raav virons |
| 01/19/2005 | EP1497435A2 Placental derived stem cells and uses thereof |
| 01/19/2005 | EP1497428A2 Surface transfection and expression procedure |
| 01/19/2005 | EP1497425A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| 01/19/2005 | EP1497419A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof |
| 01/19/2005 | EP1497412A2 Adenovirus vectors for immunotherapy |
| 01/19/2005 | EP1497328A2 Regulation of human transient receptor potential channel |
| 01/19/2005 | EP1497306A1 Alternatively spliced nucleic acid molecules |
| 01/19/2005 | EP1497305A2 Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes |
| 01/19/2005 | EP1496979A2 Protamine-adenoviral vector complexes and methods of use |
| 01/19/2005 | EP1496937A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/19/2005 | EP1496935A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/19/2005 | EP1496923A1 Cancer immunotherapy |
| 01/19/2005 | EP1496901A2 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 01/19/2005 | EP1496743A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/19/2005 | EP1392366A4 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 01/19/2005 | EP1165493B1 Nitrogen mustard compounds and prodrugs therefor |
| 01/19/2005 | EP0941116B1 Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device |
| 01/19/2005 | CN1568373A RNA interference mediating small rna molecules |
| 01/19/2005 | CN1568197A Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 01/19/2005 | CN1568194A Modulation of smooth muscle cell proliferation |
| 01/19/2005 | CN1568193A Use of il-18 inhibitors in hypersensitivity disorders |
| 01/19/2005 | CN1566348A G type non-viral vector and pharmaceutical composition containing same |
| 01/19/2005 | CN1566347A N type non-viral vector and pharmaceutical composition containing same |
| 01/19/2005 | CN1566343A Method for making chitosan nanoparticle-pcDNA3.1-hVEGF gene complex |
| 01/19/2005 | CN1566144A Functional protein in SARS coronavirus |
| 01/19/2005 | CN1566132A Schizophrenia susceptible gene----KPNB3 gene and uses thereof |